We would like to thank Dr. Margonis and colleagues for their response to our article and considerate comments. Our study had demonstrated that indeterminate extrahepatic disease in the lungs, as identified by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography had a predictive value in identifying patients at risk for site-specific recurrence.1 In their response, Margonis and colleagues had proposed the integration of Kirsten Rat Sarcoma (KRAS) mutation status to improve the prognostic impact of indeterminate colorectal lung metastases in patients being considered for resection of colorectal liver metastasis.
Wong, G. Y. M., Kumar, R., Beeke, C., Ullah, S., Chen, J., Karapetis, C. S., Price, T. J., & Padbury, R. (2018). Response to: "consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients with Colorectal Liver Metastases". Annals of Surgery, 268(1), e9-e10. https://doi.org/10.1097/SLA.0000000000002266